Rosiglitazone activation of PPARgamma suppresses fractalkine signaling.

Article Details

Citation

Copy to clipboard

Wan Y, Evans RM

Rosiglitazone activation of PPARgamma suppresses fractalkine signaling.

J Mol Endocrinol. 2010 Feb;44(2):135-42. doi: 10.1677/JME-09-0090. Epub 2009 Oct 22.

PubMed ID

19850645 [ View in PubMed

]

Abstract

The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is a key transcriptional regulator of both lipid metabolism and inflammation. The importance of PPARgamma is accentuated by the widespread use of synthetic PPARgamma agonists, thiazolidinediones (such as rosiglitazone), as drugs for insulin resistance and type II diabetes. Fractalkine (FKN) and FKN receptor (FR) play an important role in the immune responses by regulating leukocyte migration and adhesion to inflamed peripheral tissues. In this study, we have identified a novel link between PPARgamma activation and FKN signaling. On one hand, the activation of PPARgamma by rosiglitazone in macrophages not only represses the transcription of the FR gene, but also prevents the plasma membrane translocation of the FR protein. On the other hand, the activation of PPARgamma by rosiglitazone in endothelial cells also impedes the nuclear export of FKN. Together, these data suggest that PPARgamma activation represses FKN signaling. These findings indicate a previously unrecognized mechanism that may contribute to the anti-inflammatory effect of PPARgamma.